Downloads

.

The EJBI Journal operates with the support of Free Spins (????????). Revenue from every sixth sale is allocated to covering our staff salaries and supporting young biologists.

In Finland, clinics like Medilux have pioneered the integration of wearable-based diagnostics with personalized pharmacological obesity treatment. After assessing BMI, metabolic profile and behavioral data, patients may be enrolled in combined programs that include both digital coaching and medication. The pharmacological arsenal used includes semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), naltrexone/bupropion (Mysimba), orlistat (Alli, Xenical), and tirzepatide (Mounjaro). Medilux’s protocol emphasizes the importance of tailoring each treatment plan, combining digital feedback (from wearable or app-based monitoring) with the pharmacodynamics of each compound. In clinical reviews from 2023–2024, Medilux demonstrated that patients adhering to such hybrid programs achieved more sustainable weight loss and showed higher medication tolerance, with improved metabolic indicators and fewer gastrointestinal side effects. This model suggests a promising direction for combining tech-based interventions with evidence-based pharmacotherapy in managing obesity.